Day: July 14, 2020

OTTAWA, July 14, 2020 (GLOBE NEWSWIRE) — Cornerstone Capital Resources Inc. (“Cornerstone” or “the Company”) (TSXV:CGP) (Frankfurt:GWN) (Berlin:GWN) (OTC:CTNXF) today announced that its Board of Directors, upon the unanimous recommendation of an independent committee of the Board (the “Independent Committee”) and following a detailed review conducted in consultation with its financial and legal advisors, has unanimously rejected SolGold plc’s (“SolGold”) unsolicited offer to acquire Cornerstone (the “Hostile Bid”) for the second time. The Hostile Bid was formalized by SolGold on June 30, 2020 nearly a year and a half after SolGold announced its intention to make an unsolicited offer to acquire Cornerstone. The Board previously announced its first rejection of the proposed bid as outlined in Cornerstone’s press release dated March...

CHICAGO, July 14, 2020 (GLOBE NEWSWIRE) — Royal Financial, Inc. (the “Company”) (OTCQX: RYFL), incorporated under the laws of Delaware on December 15, 2004, for the purpose of serving as the holding company of Royal Savings Bank (the “Bank”), announces the preliminary earnings results and statement of condition for the fiscal year ended 2020.Net income for the fourth quarter of fiscal 2020 was $1.0 million or $0.41 per share, compared to $874,000, or $0.34 per share, for the same period in fiscal 2019.  Net income for the year ended June 30, 2020, was $2.0 million, or $0.80 per share, compared to $3.7 million, or $1.46 per share in 2019.The Company also reported total assets of $434.1 million and stockholders’ equity of $42.8 million as of June 30, 2020. At June 30, 2020, the book value per common share, shares outstanding of 2,556,518,...

SYDNEY, Australia, July 15, 2020 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 10,711,060 entitled “Antibody molecules to LAG-3 and uses thereof” by the United States Patent and Trade Mark Office.This new United States patent is directed to embodiments of LAG525, a humanised form of Immutep’s IMP701 antibody which is out-licensed to Novartis AG. In particular, the patent is directed to nucleic acid molecules that code for the LAG525 antibody, to expression vectors and host cells that comprise these nucleic acids, and to methods of producing the LAG525 antibody by culturing the host cells of the invention.The application was originally filed as a second divisional application and this grant follows the grant of the first divisional application, as announced...

MONACO, July 14, 2020 (GLOBE NEWSWIRE) — Scorpio Tankers Inc. (NYSE:STNG) (“Scorpio Tankers,” or the “Company”) announced that Scorpio Services Holdings Limited (“SSH”), a related party, has purchased 100,000 common shares of the Company in the open market at an average price of $12.83 per share.Additionally, the President of the Company, Robert Bugbee, has purchased call options on an aggregate of 550,000 common shares (or 5,500 call option contracts) of the Company for total consideration of $2.1 million.  Of these option contracts, 1,000 contracts have a strike price of $15.00 and an expiration of January 2021, and 4,500 contracts have a strike price of $18.00 and an expiration of January 2022.About Scorpio Tankers Inc.Scorpio Tankers is a provider of marine transportation of petroleum products worldwide. The Company’s fleet...

DAYTONA BEACH, Fla., July 14, 2020 (GLOBE NEWSWIRE) — CTO Realty Growth (NYSE American: CTO) (the “Company” or “CTO”) today announced the closing of the following three land sales transactions representing a total of approximately 3,110 acres and generating aggregate sales proceeds of approximately $42 million ( the “Land Sales”) to the Land Joint Venture that was formed in October 2019 (the “Land JV”):On July 14, 2020, completed the sale of approximately 3,015 acres, located on the west side of Interstate 95 (“I-95”), to an affiliate of SITEX Properties USA, including four separate land parcels, for total proceeds of approximately $40.9 million. The largest parcel of the four sold was previously under contract for the proposed second phase of the Latitude Margaritaville community;In early July 2020, completed the sale of approximately...

TORONTO, July 14, 2020 (GLOBE NEWSWIRE) — Hampton Financial Corporation (“Hampton” or the “Corporation”) (TSXV: HFC) (TSXV: HFC.PR.A) is pleased to announce that Mr. Duncan Webb will be joining the firm as President, Chief Operating Officer & Chief Financial Officer. Mr. Webb has a long history as a senior executive in Canada’s financial services industry. Prior to Joining Hampton, Mr. Webb served as Senior Vice President, Chief Financial Officer & Chief Administrative Officer with CIBC Mellon. Prior to this he served as Senior Vice President – Finance & Technology for the Ontario Pension Board. As well, he has served as Chief Compliance Officer for Credit Suisse Securities (Canada), and Chief Financial Officer for CT Securities Inc. Mr. Webb’s appointment adds significant depth to the Hampton management team and...

Angelini Pharma获得OV101（gaboxadol）开发、生产和商业化独家权利，用于欧盟、欧洲经济区其他国家以及瑞士、土耳其、英国和俄罗斯天使综合征患者的潜在治疗 Ovid Therapeutics将获得2000万美元前期付款并将在实现开发、制造和销售里程碑后再获得高达2.125亿美元的付款；此外如成功实现商业化还将获得净销售额两位数百分比的特许权收入 Angelini Pharma将通过其新成立的附属机构Angelini Pharma Rare Diseases AG来执行该项协议 Ovid将于今天上午8:15举行电话会议和网络直播 EDT纽约和罗马, July 15, 2020 (GLOBE NEWSWIRE) — 致力于开发药品以改进罕见神经系统疾病患者生活的生物制药企业Ovid Therapeutics Inc.（纳斯达克：OVID，以下称“Ovid”）与长期广泛关注精神健康、罕见病和消费者健康并致力于帮助患者的意大利家族制药企业Angelini Pharma S.p.A.（以下称“Angelini Pharma”）宣布签署协议，由Angelini Pharma负责OV101（gaboxadol）的开发、制造和商业化，作为欧盟和欧洲经济区其他国家以及瑞士、土耳其、英国及俄罗斯地区天使综合征的潜在治疗方法。Angelini Pharma将通过其新设立的附属机构Angelini Pharma Rare Diseases AG执行本协议。OV101被认为是开发中的唯一一种delta (δ)选择性GABAA受体激动剂，目前正在天使综合征关键的第三期NEPTUNE试验中进行评估，预计将在2020年第四季度获得顶线试验结果。根据协议条款， Ovid将获得2000万美元前期付款，并将在实现开发、制造以及针对首个适应症（天使综合征）的销售后获得高达2.125亿美元的付款；而如果OV101成功实现商业化则可获得相当于净销售额两位数百分比的特许费。Ovid将保留OV101在美国和世界其他地区的全部商业权利。“我们很高兴能与Angelini...

Angelini Pharma 獲得 OV101 (gaboxadol) 的獨家開發、生產和商業化權利，以治療歐盟和歐洲經濟區其他國家，及瑞士、土耳其、英國和俄羅斯的天使綜合症 如可成功實現開發、生產和銷售的里程碑，Ovid Therapeutics 將獲得 2,000 萬美元的首期付款和高達 2.125 億美元的額外付款，並在成功實現商業化後按淨銷售額獲得雙位數字的特許權使用費 Angelini Pharma 將透過新的關聯公司 Angelini Pharma Rare Diseases AG 執行上述協議 Ovid 將主持會議通話和網絡廣播，時間為今天上午 8:15 （美國東部時間）紐約和羅馬, July 15, 2020 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ：OVID，下稱「Ovid」) 是生物製藥公司，致力開發能改變罕見神經疾病患者生活，與一家由意大利家家族持有、致力幫助患者持續關注精神健康、罕見疾病和消費者健康的製藥公司 Angelini Pharma S.p.A. (下稱「Angelini Pharma」) 共同宣佈達成協議，當中 Angelini Pharma 將負責開發、生產和商業化 OV101 (gaboxadol)，以潛在治療歐盟和歐洲經濟區其他國家，及瑞士、土耳其、英國和俄羅斯的天使綜合症。Angelini Pharma 將透過新的關聯公司 Angelini Pharma Rare Diseases AG 執行上述協議。OV101 被認為是發育中唯一的 delta (δ)-選擇性 GABAA 受體激動劑，而目前在天使綜合症關鍵第 3 期 NEPTUNE 試驗中接受評估，預計主要結果將於 2020 年第四季發佈。根據協議條款，如可成功實現天使綜合症初始適應症的開發、生產和銷售的里程碑，Ovid 將獲得 2,000 萬美元的首期付款和高達 2.125 億美元的額外付款，並在成功實現商業化...

Angelini Pharma obtient les droits exclusifs de développement, de fabrication et de commercialisation d’OV101 (gaboxadol) pour le traitement potentiel du syndrome d’Angelman dans l’Union européenne et dans d’autres pays de l’Espace économique européen ainsi qu’en Suisse, en Turquie, au Royaume-Uni et en RussieOvid Therapeutics recevra un paiement initial de 20 millions USD et des paiements supplémentaires allant jusqu’à 212,5 millions USD à la réalisation des étapes de développement, de fabrication et de vente, en plus d’un pourcentage de redevances à deux chiffres sur les ventes nettes en cas de commercialisation réussie Angelini Pharma exécutera l’accord par le biais de sa nouvelle société affiliée Angelini Pharma Rare Diseases AG Ovid tiendra une conférence téléphonique et webdiffusion...

Angelini Pharma erhält Exklusivrechte für die Entwicklung, Herstellung und Vermarktung von OV101 (Gaboxadol) zur potenziellen Behandlung des Angelman-Syndroms in der Europäischen Union und anderen Ländern des Europäischen Wirtschaftsraums sowie in der Schweiz, in der Türkei, im Vereinigten Königreich und in RusslandOvid Therapeutics erhält eine Vorauszahlung in Höhe von 20 Mio. USD und zusätzliche Zahlungen in Höhe von bis zu 212,5 Mio. USD bei Erreichen von Meilensteinen in den Bereichen Entwicklung, Herstellung und Vertrieb sowie zweistellige Lizenzgebühren für den Nettoumsatz bei erfolgreicher Vermarktung Angelini Pharma wird die Vereinbarung über seine neue Tochtergesellschaft Angelini Pharma Rare Diseases AG ausführen Ovid hält heute um 8:15 Uhr EDT eine Telefonkonferenz und einen Webcast abNEW YORK (USA) und ROM (Italien), July...